Tyra BiosciencesTYRA
TYRA
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 18
36% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 25
18% more funds holding
Funds holding: 95 [Q3] → 112 (+17) [Q4]
6.27% more ownership
Funds ownership: 89.8% [Q3] → 96.07% (+6.27%) [Q4]
36% less call options, than puts
Call options by funds: $53K | Put options by funds: $83K
38% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 5 (-3) [Q4]
39% less capital invested
Capital invested by funds: $1.11B [Q3] → $676M (-$439M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
244%
upside
Avg. target
$29
257%
upside
High target
$30
269%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 43% 1-year accuracy 41 / 96 met price target | 269%upside $30 | Buy Reiterated | 31 Mar 2025 |
UBS Eliana Merle 31% 1-year accuracy 5 / 16 met price target | 244%upside $28 | Buy Initiated | 7 Jan 2025 |
Financial journalist opinion
Neutral
PRNewsWire
6 days ago
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 - CARLSBAD, Calif. , March 27, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted recent corporate progress.
Neutral
PRNewsWire
1 month ago
Tyra Biosciences to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, February 12, 2025, at 2:00 PM ET Location: Virtual TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Monday, March 3, 2025, at 9:50 AM ET Location: Boston Jefferies Biotech on the Beach Summit, March 11-12, 2025 Format: One-on-one investor meetings Location: Miami Barclays 27th Annual Global Healthcare Conference, March 11-13, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, March 12, 2025, at 8:30 AM ET Location: Miami A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
Neutral
PRNewsWire
2 months ago
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
CARLSBAD, Calif. , Jan. 22, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts were accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), taking place January 23-25, 2025, in San Francisco, CA.
Neutral
PRNewsWire
2 months ago
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
-TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif.
Neutral
24/7 Wall Street
4 months ago
Post-Election Insider Buying in These 6 Stocks Is Huge
24/7 Wall St. Insights As we race toward the end of the year, the past week brought some huge insider share purchases.
Neutral
PRNewsWire
4 months ago
Tyra Biosciences to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Jefferies London Healthcare Conference, November 19-21st, 2024: Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, November 19th, at 2:00 pm GMT.
Neutral
PRNewsWire
4 months ago
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2024, and highlighted recent corporate progress.
Neutral
PRNewsWire
5 months ago
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
– TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in Q1 2025 – CARLSBAD, Calif. , Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 for children with achondroplasia (BEACH301).
Negative
Benzinga
5 months ago
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
On Thursday, Tyra Biosciences, Inc. TYRA released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study.
Neutral
PRNewsWire
5 months ago
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
- Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif. , Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study.
Charts implemented using Lightweight Charts™